Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to elevate them to “priority asset” status. The latest evidence of the therapies’ potential comes from a phase 3 study in China of risvutatug rezetecan (ris-rez), a B7-H3-targeted ADC. The trial hit its primary endpoint of overall survival in patients with advanced or relapsed small-cell lung cancer (SCLC) w...